A new project is expected to help us understand diseases such as cancer and dementia. A major partnership involving Oxford Nanopore Technologies, UK Biobank, NHS England, Genomics England, and the UK government has made this possible.
The study, published in PLoS Biology, looked at the neurotransmitter in the brain that calculates whether to pursue a task - in other words, motivation.
Here, we learn about Daisuke Kihara, Professor of Biological Sciences and Computer Science at Purdue University, who develops state-of-the-art computational methods for modelling 3D structures of protein complexes.
The study, published in The Lancet Digital Health, found that deep learning tech had an average accuracy of 88% when it came to diagnosing genetic syndromes.
Ute Deichmann of the Jacques Loeb Centre for the History and Philosophy of the Life Sciences at Ben-Gurion University, explores the role hierarchical causal models have on constancy and plasticity in biology.
A study, published in the journal DNA Repair, finds that hydroxychloroquine (HCQ) is potentially toxic to mammals - the drug that was previously elevated to the status of miracle COVID cure in some circles.
Dr Jen Vanderhoven, Director, National Horizons Centre, Teesside University, sheds some light on how the gene therapy field can progress in the face of funding challenges and skills shortages.
A team at Newcastle University have identified a gene, HLA-DRB1*04:01, which could be responsible for individuals who are asymptomatic - suggesting that the gene offers some protection against severe COVID.
Graham Brookes, Agricultural Economist with PG Economics, UK, charts how the development and deployment of COVID-19 vaccines, derived using techniques of genetic modification, highlight ideological inconsistency and hypocrisy.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechCasting Group, provides a portrait of a ground-breaking technology, next-generation sequencing, starting with a brief snapshot.
The idea is still at an early stage, but initial clinical study results show that immunotherapy against type 1 diabetes could function as a 'diabetes vaccine.'
Three academic experts, including Richard E. Goodman from the Food Allergy Research and Resource Program, shed light on defeating late blight disease of potato in sub-Saharan Africa, starting with a brief introduction to the crop in question.
